AstraZeneca (AZN) Reports Q4 EPS of $1.30

AstraZeneca (NYSE: AZN) reported Q4 EPS of $1.30, $0.83 better than the analyst estimate of $0.47. Revenue for the quarter came in at $5.78 billion versus the consensus estimate of $5.45 billion.

GUIDANCE:

AstraZeneca sees FY2018 EPS of $3.30-$3.50, versus the consensus of $1.62.

For earnings history and earnings-related data on AstraZeneca (AZN) click here.

You May Also Be Interested In

• Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NS
• Lucid reports Q2 output, names new CFO and five other leaders
• AI chip winners may face tougher road ahead as hyperscalers catch up: JPM